GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Restart Life Sciences Corp (OTCPK:NMLSF) » Definitions » Capex-to-Operating-Cash-Flow

NMLSF (Restart Life Sciences) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Restart Life Sciences Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Restart Life Sciences's Capital Expenditure for the three months ended in Dec. 2024 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2024 was $-0.01 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Restart Life Sciences Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Restart Life Sciences's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Restart Life Sciences Capex-to-Operating-Cash-Flow Chart

Restart Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Restart Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Restart Life Sciences's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Restart Life Sciences's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Restart Life Sciences's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Restart Life Sciences's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Restart Life Sciences's Capex-to-Operating-Cash-Flow falls into.


;
;

Restart Life Sciences Capex-to-Operating-Cash-Flow Calculation

Restart Life Sciences's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.051
=N/A

Restart Life Sciences's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.008
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Restart Life Sciences  (OTCPK:NMLSF) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Restart Life Sciences Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Restart Life Sciences's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Restart Life Sciences Business Description

Traded in Other Exchanges
Address
700 - 838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Restart Life Sciences Corp is a Canadian life sciences company dedicated to addressing today's health challenges with wellness solutions. Its focus is on creating health foods that address the needs of this community. Its flagship developments include natural remedies for individuals on the Autism Spectrum, Specialty Health Foods, Psilocybin Clinical Trial for Fragile X Syndrome, and Orphan Drug Designation (FDA and EMA). The company operates in one industry segment, being research and development of psilocybin, and in one geographic area, being Canada.

Restart Life Sciences Headlines

From GuruFocus

Nova Mentis Announces Closing of Non-Brokered Financing

By PRNewswire PRNewswire 03-15-2022

U.S. FDA Approves Nova Mentis Orphan Drug Application

By PRNewswire PRNewswire 11-02-2021